GWAS meta-analysis provides new insights into uveal melanoma risk.

Br J CancerJun 16, 2026 (epub)
Clinical ResearchMedical GeneticsOncology (Medical)Open access

Matthew D'Mellow, Huanwei Wang, Jane M Palmer et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis investigated germline genetic variants associated with uveal melanoma (UM) using data from nine studies comprising 5,839 UM cases and 349,863 healthy controls. The study identified nine linkage disequilibrium-independent loci, including three novel loci, with a significant IVW P value of less than 5 × 10^-8. Additionally, a genetic correlation was found between UM and cutaneous melanoma.

Key findings

  • Nine linkage disequilibrium-independent loci were identified, three of which are novel.
  • The meta-analysis achieved an IVW P value of less than 5 × 10^-8.
  • A significant genetic correlation (rg = 0.31, P = 0.01) was observed between UM and cutaneous melanoma.
  • Five potential target genes linked to UM risk were identified through TWAS analysis.

Why it matters

Understanding the genetic predisposition to uveal melanoma can aid in identifying at-risk individuals and developing targeted therapies. Insights into genetic correlations with other melanoma types may enhance overall melanoma management strategies.

Source

PubMed · PMID 42303830Free full text on PubMed Central

Published in Br J Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Medical Genetics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.